SG Americas Securities LLC Acquires 126,702 Shares of Bio-Techne Corp $TECH

Key Points

• SG Americas Securities LLC increased its stake in Bio‑Techne by 1,275.2% in Q4, acquiring 126,702 shares to hold 136,638 shares worth about $8.04 million (≈0.09% of the company).
• Bio‑Techne beat Q4 expectations with EPS $0.46 vs. $0.43 consensus and revenue of $295.9M vs. $290.2M expected, though revenue was down 0.4% year‑over‑year.
• Wall Street sentiment is broadly positive with an average rating of "Moderate Buy" and a consensus price target of $72.77, compared with a recent share price near $52.04.

SG Americas Securities LLC lifted its stake in Bio-Techne Corp (NASDAQ:TECH - Free Report) by 1,275.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 136,638 shares of the biotechnology company's stock after acquiring an additional 126,702 shares during the quarter. SG Americas Securities LLC owned approximately 0.09% of Bio-Techne worth $8,036,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in shares of Bio-Techne by 109.7% in the 3rd quarter. Blue Trust Inc. now owns 453 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 237 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in shares of Bio-Techne in the third quarter valued at about $32,000. iSAM Funds UK Ltd bought a new position in shares of Bio-Techne during the third quarter worth approximately $33,000. Sound Income Strategies LLC acquired a new stake in Bio-Techne during the third quarter worth approximately $37,000. Finally, Federated Hermes Inc. bought a new position in Bio-Techne during the 3rd quarter worth $37,000. 98.95% of the stock is owned by institutional investors.

Bio-Techne Stock Performance

NASDAQ TECH opened at $52.04 on Tuesday. Bio-Techne Corp has a twelve month low of $46.01 and a twelve month high of $72.16. The company has a quick ratio of 3.08, a current ratio of 4.54 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $8.14 billion, a price-to-earnings ratio of 102.04, a PEG ratio of 3.35 and a beta of 1.48. The stock has a fifty day simple moving average of $58.92 and a 200 day simple moving average of $59.77.

Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.43 by $0.03. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The business had revenue of $295.88 million for the quarter, compared to analysts' expectations of $290.20 million. During the same period in the prior year, the business posted $0.42 earnings per share. The firm's revenue was down .4% on a year-over-year basis. Sell-side analysts expect that Bio-Techne Corp will post 1.67 EPS for the current year.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, February 27th. Investors of record on Monday, February 16th were paid a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, February 13th. Bio-Techne's dividend payout ratio (DPR) is currently 62.75%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TECH. Evercore increased their target price on Bio-Techne from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Thursday, February 5th. Robert W. Baird set a $70.00 price objective on shares of Bio-Techne in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft set a $72.00 price objective on shares of Bio-Techne and gave the stock a "buy" rating in a research note on Friday, December 12th. Benchmark restated a "buy" rating on shares of Bio-Techne in a research report on Tuesday, February 3rd. Finally, Wells Fargo & Company upped their price objective on Bio-Techne from $70.00 to $76.00 and gave the stock an "overweight" rating in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $72.77.

Bio-Techne Profile

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.